Sipai Health Technology Co., Ltd. provided consolidated earnings guidance for the six months ended June 30, 2023. The group expects that, due to (i) the organic growth in the overall business of the Group, (ii) the fair value losses on the Company's convertible redeemable preferred shares issued to pre-IPO investors as financial liabilities at fair value through profit or loss ("FVTPL") did not recur for the Period after the completion of the Company's listing of its shares on The Stock Exchange of Hong Kong Limited in December 2022 (the "Listing"), (iii) the listing expenses did not recur for the Period after the completion of the Listing, and (iv) the decrease in the share-based payment compensation during the Period, both the adjusted loss (non-IFRS measure) for the period and the loss for the period for the six months ended June 30, 2023 may be narrowed by more than 70% as compared to the adjusted loss (non-IFRS measure) for the period of RMB 143.11 million and the loss for the period of RMB 345.99 million for the corresponding period in 2022, respectively.